Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05388669
Study type Interventional
Source Janssen Research & Development, LLC
Contact
Status Active, not recruiting
Phase Phase 3
Start date August 5, 2022
Completion date January 9, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05450692 - A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy Phase 3
Recruiting NCT05621525 - Phase I Study of the BBP-398 in Patients With Advance Solid Tumors Phase 1
Completed NCT00716534 - Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT02855125 - A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 Phase 2